Image For Activity Cover
Advancing the Science in Pediatric Achondroplasia
Course Description
This symposium will explore the natural history of, the clinical challenges to, and role of the FGFR3 gene in pediatric achondroplasia. World-renowned experts will highlight best practices in collaborative care, novel treatments, and disease-specific tool to monitor children with achondroplasia, to advance and improve patient care.
Target Audience
Endocrinologists & Pediatric Endocrinologists
Learning Objectives
During this educational activity, faculty will:
  • Discuss the natural history and clinical challenges in pediatric achondroplasia
  • Describe the importance of the FGFR3 gene in the pathophysiology and future treatment
    of achondroplasia
  • Review best practices in the collaborative care of children with achondroplasia and potential practice changes with the introduction of novel treatments
  • Explain the importance of using disease-specific charts and tools to monitor children
    with achondroplasia
Accreditation Statement

The Endocrine Society is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. Endocrine Society has achieved Accreditation with Commendation.

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Endocrine Society and Science Collected. The Endocrine Society is accredited by the ACCME to provide continuing medical education for physicians. 

AMA PRA Category 1 Credit
The Endocrine Society designates each activity in this course for a maximum of 1.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. While offering CME credits noted above, this program is not intended to provide extensive training or certification in the field.

Please note that while other accrediting bodies accept AMA PRA Category 1 credit, we can only award and report this credit for MDs/DOs. For those outside of this accreditation, please complete the participation evaluation and use that certificate as proof of attendance to submit to your accrediting body.

Maintenance of Certification (MOC)
Successful completion of each CME activity in this course, which includes participation in the evaluation component, enables the participant to earn up to 1.50 points in the American Board of Pediatrics (ABP) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABP MOC credit.

For questions about content or obtaining CME credit, please contact the Endocrine Society at

Faculty and Disclosures

Andrew Dauber, MD – Program Chair
Children's National Hospital
Washington, DC

Nadia Merchant, MD
Children's National Hospital
Washington, DC

Aristides Maniatis, MD
Rocky Mountain Pediatric Endocrinology
Centennial, CO

As a provider of CME accredited by the Accreditation Council for Continuing Medical Education, the Endocrine Society has a policy of ensuring that the content and quality of this educational activity are balanced, independent, objective, and scientifically rigorous. The scientific content of this activity was developed under the supervision of the Endocrine Society’s guideline task force.

The faculty, committee members, and staff who are in position to control the content of this activity are required to disclose to the Endocrine Society and to learners any relevant financial relationship(s) of the individual or spouse/partner that have occurred within the last 12 months with any commercial interest(s) whose products or services are related to the content. Financial relationships are defined by remuneration in any amount from the commercial interest(s) in the form of grants; research support; consulting fees; salary; ownership interest (e.g., stocks, stock options, or ownership interest excluding diversified mutual funds); honoraria or other payments for participation in speakers' bureaus, advisory boards, or boards of directors; or other financial benefits. The intent of this disclosure is not to prevent planners with relevant financial relationships from planning or delivery of content, but rather to provide learners with information that allows them to make their own judgments of whether these financial relationships may have influenced the educational activity with regard to exposition or conclusion.

The Endocrine Society has reviewed these relationships to determine which are relevant to the content of this activity and resolved any identified conflicts of interest for these individuals.

The faculty reported the following relevant financial relationship(s) during the content development process for this activity:

  • Andrew Dauber, MD: Biomarin, Advisory board, grantee; Novo Nordisk, Consultant, Advisory Board; Ascendis, Advisory Board; Pfizer, Advisory Board
  • Nadia Merchant, MD: Pfizer, Advisory Board; BioMarin, Co-PI for investigator initiated study, Advisory Board
  • Aristides Maniatis, MD: Alexion, Principal Investigator; Ascendis, Principal Investigator, Speaker Bureau, Advisory Board; Novo Nordisk, Principal Investigator; Pfizer/OPKO, Principal Investigator; Aeterna Zentaris, Adjudication Committee; BioMarin, Speaker Bureau, Advisory Board; Novo Nordisk, Speaker Bureau, Advisory Board; Pfizer, Advisory Board

The following committee member who planned and reviewed content for this activity reported the following relevant financial relationships:

  • Panagiota Andreopoulou, MD - Weill Medical College, Cornell University

The Endocrine Society staff involved in the development of this CME activity reported no relevant financial relationships.

The Endocrine Society staff have reviewed all disclosures and resolved or managed all relevant identified conflicts of interest, as applicable.

This educational activity is supported by educational grant from BioMarin Pharmaceuticals.

Availability: Retired
Cost: FREE
Credit Offered:
No Credit Offered
     EndoCareers | Contact Us | Privacy Policy | Terms of Use CONNECT WITH US                
       © 2021 Copyright Endocrine Society. All rights reserved.
2055 L Street NW, Suite 600 | Washington, DC 20036      
 202.971.3636 | 888.363.6274
Android App Download IOS App Download Powered By